Halozyme Therapeutics Inc (HALO)

[OncoJock]

News like this makes me want to buy more shares.

“As seen in the PALOMA-3 study, with its significantly shorter administration time and five-fold reduction in infusion-related reactions, alongside longer overall survival, progression-free survival and duration of response, I look forward to seeing how subcutaneous amivantamab can make a meaningful difference in clinical practice,” Natasha B. Leighl, MD, medical oncologist at the Princess Margaret Cancer Centre in Toronto, Canada, and clinical trial investigator on PALOMA-3, told Targeted OncologyTM.

Source: https://www.targetedonc.com/view/fda-considers-subcutaneous-amivantamab-in-egfr-mutated-nsclc